Compare GSK Pharma with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs VENUS REMEDIES - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA VENUS REMEDIES GSK PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 33.0 -1.1 - View Chart
P/BV x 13.1 0.1 17,423.5% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
VENUS REMEDIES
Mar-18
GSK PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs3,595126 2,855.4%   
Low Rs1,25361 2,050.7%   
Sales per share (Unadj.) Rs184.7301.8 61.2%  
Earnings per share (Unadj.) Rs26.3-24.9 -105.7%  
Cash flow per share (Unadj.) Rs29.22.5 1,146.0%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs126.3293.3 43.1%  
Shares outstanding (eoy) m169.4012.34 1,372.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.10.3 4,237.0%   
Avg P/E ratio x92.2-3.8 -2,452.3%  
P/CF ratio (eoy) x83.136.7 226.2%  
Price / Book Value ratio x19.20.3 6,019.2%  
Dividend payout %76.10-   
Avg Mkt Cap Rs m410,6261,154 35,589.3%   
No. of employees `0005.00.9 536.2%   
Total wages/salary Rs m5,372393 1,366.6%   
Avg. sales/employee Rs Th6,306.74,026.1 156.6%   
Avg. wages/employee Rs Th1,083.1425.0 254.9%   
Avg. net profit/employee Rs Th898.0-331.8 -270.7%   
INCOME DATA
Net Sales Rs m31,2813,724 840.0%  
Other income Rs m1,02323 4,547.4%   
Total revenues Rs m32,3043,747 862.2%   
Gross profit Rs m6,009395 1,522.0%  
Depreciation Rs m486338 143.7%   
Interest Rs m6354 1.7%   
Profit before tax Rs m6,540-275 -2,375.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,37332 7,509.5%   
Profit after tax Rs m4,454-307 -1,451.3%  
Gross profit margin %19.210.6 181.2%  
Effective tax rate %36.3-11.5 -316.1%   
Net profit margin %14.2-8.2 -172.8%  
BALANCE SHEET DATA
Current assets Rs m20,0612,638 760.6%   
Current liabilities Rs m14,5432,305 631.0%   
Net working cap to sales %17.68.9 197.3%  
Current ratio x1.41.1 120.5%  
Inventory Days Days57135 41.9%  
Debtors Days Days1446 30.3%  
Net fixed assets Rs m14,3434,871 294.5%   
Share capital Rs m1,694123 1,372.8%   
"Free" reserves Rs m19,7043,496 563.7%   
Net worth Rs m21,3983,619 591.3%   
Long term debt Rs m21,374 0.1%   
Total assets Rs m39,1137,509 520.9%  
Interest coverage x1,091.00.2 489,292.8%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.80.5 161.2%   
Return on assets %11.40.6 1,806.3%  
Return on equity %20.8-8.5 -245.5%  
Return on capital %31.91.6 2,018.2%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m5340-   
Fx outflow Rs m7,091517 1,372.9%   
Net fx Rs m-6,557-517 1,269.5%   
CASH FLOW
From Operations Rs m3,994514 776.4%  
From Investments Rs m-1,433-123 1,164.4%  
From Financial Activity Rs m-3,584-387 925.8%  
Net Cashflow Rs m-1,0234 -24,361.9%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.2 5,666.7%  
FIIs % 23.8 0.6 4,103.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 66.4 23.2%  
Shareholders   102,036 20,121 507.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  SANOFI INDIA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 16.6% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 16.6% YoY). Sales on the other hand came in at Rs 8 bn (up 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 20, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS